

## Secondary prevention meds often not started post-AMI in seniors

October 26 2017

---



(HealthDay)—Thirty-seven percent of older nursing home (NH)

residents do not initiate secondary prevention medications after acute myocardial infarction (AMI), according to a study published online Oct. 17 in the *Journal of the American Geriatrics Society*.

Andrew R. Zullo, Pharm.D., Ph.D., from Brown University in Providence, Rhode Island, and colleagues performed a [retrospective cohort study](#) to assess new use of secondary prevention medications after AMI in NH residents who were previously nonusers. Data were included for 11,192 NH residents aged 65 years and older who were hospitalized for an AMI between May 2007 and March 2010.

The researchers found that 37, 41, and 22 percent of residents had no, one, and two secondary prevention medications initiated after AMI. After adjustment for covariates, fewer secondary prevention medications were used in older residents; women; and those with a do-not-resuscitate order, functional impairment, and cognitive impairment (proportional odds ratios, 0.48, 0.88, 0.9, 0.77, and 0.79, respectively).

"More than one-third of older NH residents in the United States do not have any secondary prevention medications initiated after AMI," the authors write. "A lack of evidence about the safety and effectiveness of secondary prevention medications in the NH population and unmeasured person-centered goals of care are plausible explanations for these findings."

One author disclosed ties to UnitedHealth Group; a second disclosed ties to iodine.com; HCR ManorCare Inc. provided data used in the study.

**More information:** [Abstract](#)  
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Secondary prevention meds often not started post-AMI in seniors (2017, October 26)  
retrieved 11 May 2024 from <https://medicalxpress.com/news/2017-10-secondary-meds-post-ami-seniors.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.